ZUMA trials

The ZUMA trials were clinical studies testing a cancer treatment called CAR T-cell therapy, specifically axicabtagene ciloleucel (Yescarta). Researchers collected patients with certain blood cancers, like large B-cell lymphoma, and treated them with modified immune cells designed to recognize and attack cancer. The trials showed that many patients responded positively, with some achieving complete remission. These results led to FDA approval, offering a new, targeted option for patients with difficult-to-treat blood cancers. Overall, the ZUMA trials helped demonstrate the safety and effectiveness of CAR T-cell therapy for specific lymphoma types.